Tuesday, June 4, 2024

This is one the most important videos you will watch this year! June 9, 2024

 

Corona Virus
Reader comments: 
BeS, thank you very much for your diligent digging/research!

This is Dr David Martin's May 2023 presentation to European Union on Cov History.  He quotes written statements that the Vaccine with Media help must drive enough fear that everyone will want the vaccine which will result in Large Profits for Pharma Investors. 
This 22 minute video also includes his presentation slides with source  info so you can investigate yourself.


I search deep in the internet but cannot find earlier presentations likely given in 2021 and 2022.



Who is Dr Martin?

Dr. David Martin is the founding CEO of M∙CAM Inc. M∙CAM is the international leader in intellectual property-based financial risk management. From auditing patent quality for governments and patent offices, to providing state-of-the-art actuarial risk management systems and solutions to the largest banks and insurance companies, M∙CAM has established a global standard in patent quality and commercial validity assessment and management.

A spokesperson for global intellectual property accountability and quality reform, Dr. Martin has worked closely with the United States Congress, numerous trade and finance regulatory agencies in the United States, Europe and Asia, in advocating and deploying infrastructure to support growing reliance on proprietary rights in business transactions. M∙CAM has supported the modernization of intellectual property, tax, and accounting laws through its work with oversight agencies and policy makers.

Dr. Martin has founded several for-profit and non-profit companies and organizations and serves of several boards. He was the founding CEO of Mosaic Technologies Inc., a company that developed and commercialized advanced computational linguistics technologies, dynamic data compression and encryption technologies, electrical field transmission technology, medical diagnostics, and stealth/anechoic technology. He was a founding member of Japan’s Institute for Interface Science & Technology. He founded and served as Executive Director of the Charlottesville Venture Group. He has served as a board member for the Research Institute for Small and Emerging Business (Washington D.C.), the Academy for Augmenting Grassroots Technological Innovations (India), the IST (Japan) the Charlottesville Regional Chamber of Commerce (Virginia), and the Charlottesville Industrial Development Agency (Virginia).

As former Assistant Professor at the University of Virginia’s School of Medicine, Dr. Martin founded the University’s first wholly-owned, for-profit, research and development and technology transfer corporation. Engaged in domestic and international technology transfer, clinical research, and financing, this company pioneered new techniques innovation management that have become industry standards. In 1999, Dr. Martin was appointed by the Governor of the Commonwealth of Virginia to serve on the Joint Commission on Technology and Science and has served the General Assembly and Virginia’s Center for Innovative Technology on numerous occasions.

Dr. Martin’s work with the Batten Institute at the Darden Graduate School of Business Administration at the University of Virginia and his related work at the Indian Institute for Management in Ahmedabad India has brought unprecedented curricular focus to areas of intangible asset risk management, finance, and accounting standards. In addition to his academic work, Dr. Martin has closely advised intellectual property based finance and investment programs in India, China, Denmark, the European Union, the United Kingdom, South Africa, the Islamic Republic of Iran, the United States, and the United Arab Emirates.

Dr. Martin has publications in law, medicine, engineering, finance and education. He maintains active research in the fields of linguistic genomics, fractal financial risk modeling, as well as continuing his over 15 years of research in cellular membrane ionic signaling.   

No comments:

Post a Comment